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Abstract
Objective—To determine the efficacy of yoga in alleviating VMS frequency and bother.
Methods—Three by two factorial design, randomized, controlled. Eligible women were
randomized to yoga (n=107), exercise (n=106), or usual activity (n=142), and were simultaneously
randomized to double-blind comparison of omega-3 fatty acid (n=177) or placebo (n=178)
capsules. Yoga intervention was twelve, weekly, 90-minute yoga classes with daily home practice.
Primary outcomes were VMS frequency and bother assessed by daily diaries at baseline, 6, and 12
weeks. Secondary outcomes included insomnia symptoms (Insomnia Severity Index) at baseline
and 12 weeks.
Results—Among 249 randomized women, 237 (95%) completed 12-week assessments. Mean
baseline VMS frequency was 7.4/day (95% CI 6.6, 8.1) in the yoga group and 8.0/day (95% CI
7.3, 8.7) in the usual activity group. Intent-to-treat analyses included all participants with response
data (n=237). There was no difference between intervention groups in change in VMS frequency
from baseline to 6 and 12 weeks (mean difference (yoga – usual activity) from baseline −0.3 (95%
CI −1.1, 0.5) at 6 weeks and −0.3 (95% CI −1.2, 0.6) at 12 weeks (p=0.119 across both time
points). Results were similar for VMS bother. At week 12, yoga was associated with an
improvement in insomnia symptoms (mean difference [yoga-usual activity] in change –Insomnia
Severity Index, 1.3 [95% CI −2.5, −0.1][p=0.007]).
Conclusion—Among healthy women, 12 weeks of yoga class plus home practice compared with
usual activity did not improve VMS frequency or bother, but reduced insomnia symptoms.
Keywords
clinical trials network; vasomotor symptoms; yoga; meditation; menopause; hot flashes
INTRODUCTION
Hormonal agents have been the predominant therapy for menopausal vasomotor symptoms
(VMS: hot flashes plus night sweats), but their use decreased substantially with shifts in our
understanding of the risk and benefits identified in the Women’s Health Initiative. 1–3
However, no other treatments have Food and Drug Administration approval for VMS.
Alternatives to hormone therapy (HT) have been explored. To date, selective serotonin
reuptake inhibitors have demonstrated modest efficacy for relief of menopause symptoms,4
while the search for mind-body therapies,5 herbal treatments,6 and supplements to lessen
menopausal symptoms continues with limited success.
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Yoga is a mind-body therapy that includes stretching, poses that require balance and core
strength, deep breathing, and meditation.7 In 2007, 6.1% of the adult U.S. population
reported practicing yoga,8 and women are almost four times as likely to practice yoga than
men.9 Population–based surveys indicate that some women use yoga in an attempt to
manage their menopause symptoms.10, 11 Yoga has been investigated as a therapy for VMS,
but studies to date have been limited in size or methodology and results have been
mixed.12–17 We evaluated the efficacy of a yoga program designed to reduce the frequency
and bother of vasomotor symptoms (VMS).
The rationale for evaluating yoga was based on hypothesized physiologic changes that occur
with menopause (or estrogen withdrawal).18 Menopause is associated with a narrowing in
the range of core body temperatures at which physiologic responses to induce cooling or
heating occur.19 These changes appear to be regulated by central noradrenergic
neurotransmitters and sympathetic nervous system (SNS) regulation, specifically an increase
in norepinephrine.18, 20, 21 The hypothesis that central noradrenergic neurotransmitters and
sympathetic nervous system (SNS) regulation affect VMS is supported by clinical and
anecdotal reports linking psychological stress and SNS regulation and VMS.22–25 Yoga may
decrease autonomic arousal through changes in the levels of circulating neurotransmitters
and hormones.26 These changes would reduce the SNS activation that has been implicated in
VMS etiology. Behavioral interventions can impact both SNS and parasympathetic nervous
system functioning and stress reactivity,27–30 raising the possibility that yoga might decrease
menopausal VMS through its impact on these finely balanced systems.
METHODS
Study design
Details about the MsFLASH Research Network, study design, and protocols have been
published.31, 32 This study was a multi-site, 3 by 2 factorial, randomized, controlled trial.
Eligible women were randomized to 12 weeks of yoga, exercise, or usual activity, and
simultaneously randomized to 1.8 g/day of omega-3 fish oil capsules (EPA 1275 mg, DHA
300 mg) or placebo capsules. The factorial design was motivated by the desire to have all
participants receive some intervention and hence have an expectancy of benefit (though
participants taking pills knew they could be on either placebo or omega-3s), and to reduce
costs. No head-to-head comparisons between yoga and exercise were planned. Interactions
between the behavioral interventions and omega-3 fatty acids were hypothesized to be
unlikely. This report describes the results of the yoga intervention compared to usual
activity; results for the exercise and omega-3 comparisons are reported separately. The study
was approved by the Institutional Review Boards of each clinical site and the Data
Coordinating Center (DCC), and all participants provided written informed consent.
Yoga intervention
No single standardized yoga practice could be identified as most appropriate for relief of
menopause symptoms. Investigators (KJS, CBL) worked with expert yoga instructors and
consultants from the National Center for Complementary and Alternative Medicine to create
a program that emphasized the practice of “cooling” breathing exercises and three groups of
poses (Asanas) believed to be useful for relieving VMS.12, 33 We sequenced poses according
to the principles of Viniyoga34 to promote safety.
Class Content—Yoga instruction was provided during 12 weekly 90-minute classes. Each
class included breathing exercises, 11 to 13 poses (restorative, inverted, lateral bends, twists,
forward bends, and counter poses), and deep relaxation featuring Yoga Nidra (a meditative
practice). Three different sequences of poses were used to increase variety and maintain
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participant interest. Women joined class as they were recruited. Before her first class, each
woman met with the instructor for 30 minutes to discuss health concerns and learn the
breathing exercises.
Home Practice—Home practice included breathing, poses, and Yoga Nidra. Participants
were given written instructions, a DVD with the 3 sequences of poses, a CD for Yoga Nidra,
and supplies (bolster, strap, blanket, and mat). Participants were instructed to practice at
home 20 minutes each day they did not attend class, alternating poses one day with Yoga
Nidra the next.
Classes were offered twice weekly. Yoga instructors had at least 5 years of teaching
experience and 500 hours of training. Yoga consultants conducted two-day trainings at each
study site. Instructors were taught to strictly adhere to the protocol. A research staff member
attended every yoga class and completed a yoga protocol adherence log. Investigators (KJS,
CBL) were in weekly contact with the instructors via email to discuss class experiences,
adverse events, adherence, and other questions.
Usual activity comparison group
Women in the usual activity group were instructed to follow their usual routine and were
asked not to engage in yoga or to change their exercise routines. At study end they were
offered their choice of a 3-hour yoga workshop or a one-month gym membership.
Eligibility, screening, randomization and blinding
The trial was conducted at three MsFLASH sites – Indianapolis, Oakland, and Seattle.
Participants were recruited from February 2011 through January 2012, primarily by mass
mailing to age-eligible women using purchased lists and health-plan enrollment files.
Eligible women were ages 40–62 years; in the menopausal transition or postmenopausal or
had a hysterectomy with FSH >20 mIU/mL and estradiol ≤50 pg/mL; and in general good
health. The VMS eligibility criteria were: ≥14 hot flashes/night sweats per week recorded on
daily VMS diaries for 3 weeks; VMS rated as bothersome or severe on 4 or more occasions
per week; and the VMS frequency in week 3 did not decrease >50% from the average
weekly levels in weeks 1 and 2. Exclusion criteria included: BMI>37; use of hormonal
contraceptives or hormones in the past month; use of prescription or over-the-counter
treatments for VMS in the past month; unstable medical conditions; current user of one of
the study interventions or a related activity (i.e., yoga, tai chi, qi gong, or meditation, regular
exercise, omega-3 fatty acid supplements, frequent consumption of fish); contraindications
to exercise (e.g., physical limitations), yoga, or omega-3 (e.g., allergy to soy or fish); or a
major depressive episode in the past 3 months.
Data collection
Following telephone screening, women completed a two-week VMS diary and a
questionnaire. Women who remained eligible attended an in-person visit that included a
blood draw, physical measures, and an additional baseline questionnaire. Following that
visit, women completed the week-3 VMS diary. Women then returned to the clinic for a
final determination of eligibility and randomization.
Randomization was conducted in a secure web-based database, maintained at the MsFLASH
DCC utilizing a dynamic randomization algorithm to maintain comparability between study
groups with respect to clinical site. For the behavioral interventions, a 3:3:4
(yoga:exercise:control) allocation was employed to improve power for intervention versus
control contrasts while reducing costs. Local access to information on assignment to yoga,
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exercise, or usual activity was limited to site staff involved in intervention delivery to assure
masking of data collectors. Equal allocation was used for omega-3 and placebo treatments.
Follow-up
At week 2, participants were contacted by study staff blinded to omega-3 assignment to
encourage compliance and to evaluate tolerance to the study capsules. During intervention
weeks 6 and 12, participants completed 7-day VMS diaries. All other baseline
measurements were repeated either during week 12 or at the week-12 clinic visit.
Participants were compensated $50 for their time and effort after each clinic visit for a
possible total of $150.
Measurements
The primary outcomes were VMS frequency and bother based on daily diaries4 in which
participants entered the number of VMS they had experienced upon awakening for
nighttime symptoms and before going to sleep for daytime symptoms. They rated VMS
bother for each day on a 1–4 scale (none, a little, moderately, and a lot).
The secondary outcomes were subjective sleep quality and sleep disturbances (Pittsburgh
Sleep Quality Index - PSQI) 35, insomnia symptoms (Insomnia Severity Index - ISI)36,
depressive symptoms (Patient Health Questionnaire depression domains - PHQ-8)37 and
anxiety (Generalized Anxiety Disorder questionnaire - GAD-7)38.
Adverse events (AEs) were assessed using a self-reported questionnaire listing 15 common
AEs related to yoga, physical activity, and omega-3 fatty acids. Participants were instructed
to call the study nurse to report any potential AEs during the study. Newly-emergent AEs
were identified by comparing AE reports during treatment to the baseline reports.
Statistical analysis
Baseline characteristics were compared between treatment groups using t-tests or chi-square
tests. The primary intent-to-treat analysis (ITT) included all randomized participants with
response data, which were collected regardless of intervention adherence. Among 249
women who were randomized, 237 (95.2%) provided week-12 response data (Figure 1).
Baseline VMS frequency was calculated as the mean of the daily totals reported for the first
two screening weeks. VMS frequency at weeks 6 and 12 were calculated as the mean of the
daily frequencies for those weeks. Baseline, week 6, and week 12 bother were also defined
as the means of the daily ratings. A categorical variable to indicate clinical VMS
improvement was defined as ≥50% decrease in VMS frequency at 12 weeks from baseline.
Intervention arm contrasts were computed as Wald statistics from linear regression models
summarizing the VMS frequency or bother at weeks 6 and 12 as a function of randomization
assignment, adjusted for clinical site, visit (week 6 or 12), omega-3 intervention assignment,
and baseline outcome value. Natural logarithmic transformations were applied to hot flash
frequencies to accommodate modeling assumptions. Robust standard errors were calculated
via generalized estimating equations to account for correlations between repeated measures
from each participant.
Variables hypothesized a priori to modify treatment response on VMS frequency included
prior experience with yoga and/or meditation, depressive symptoms (PHQ-8 continuous
score), anxiety (GAD-7, continuous score), body mass index (BMI: < 25 kg/m2, 25 to <30
kg/m2, ≥ 30 kg/m2), and race (African American, white). Tests for interaction between these
variables and treatment assignment were performed within the linear regression model.
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We defined adherence as completing 4 or more sessions in a week and tracked adherence
weekly. The number of sessions completed per week (up to 4 maximum) was summed over
12 weeks and percent adherence was calculated as the total number of sessions divided by
48 (missing diaries were calculated as zero participation).
Secondary analyses also applied linear regression to model changes in measures of
subjective sleep quality and sleep disturbances (PSQI 35), insomnia symptoms (ISI 36),
depressive symptoms (PHQ-8 37), and anxiety (GAD-738), as a function of treatment
assignment, following a similar approach to that used with primary analyses. Incidence of
newly emergent adverse events was compared between groups using Fisher's exact test.
Multiple comparisons determined our choice of what p values would be considered
statistically significant. A 2-sided p value < 0.025 was considered statistically significant for
the two primary outcomes. For the four outcomes examined as secondary analyses, a p-value
less than 0.0125 was considered statistically significant. Analyses were conducted using
SAS version 9.2 (SAS Institute, Cary, NC).
A sample of 112 yoga participants and 150 usual activity participants was planned to
provide 90% power to detect a mean difference of 1.9 VMS/day reduction between groups
(a 0.49 standard deviation (SD) reduction in VMS/day, based on the variability observed in
preliminary data from the first 97 participants enrolled in the MsFLASH escitalopram trial 4.
This calculation was based on a t-test with 2-sided significance level of 0.025 to account for
two primary outcomes (VMS frequency, VMS bother), allowing for 10% loss to follow-up
in both arms and an extra 10% in the exercise arm to address the potential for increased
variability in outcomes due to differing adherence to the intervention.
RESULTS
Among 249 women, 107 were randomly assigned to receive yoga and 142 were assigned to
usual activity (Figure 1). There were no significant differences in baseline characteristics
between the two intervention groups. The mean age of participants was 54 years, 63% were
white, most were postmenopausal and well educated, mean BMI was 27 kg/m2, and few
were smokers (Table 1). Follow-up rates among the intervention and usual activity groups
were 96% and 95% at 6 weeks, and 94% and 95% at 12 weeks, respectively, with no
differences between groups.
Vasomotor symptom frequency and bother
The mean baseline VMS frequency was 7.4/day (95% CI 6.6, 8.1) in the yoga group and 8.0/
day (95% CI 7.3, 8.7) in the usual activity group with a range of 2.1–21.4 VMS per day
(Table 2). Yoga did not significantly reduce the frequency of VMS relative to usual activity,
adjusted for site, visit (week 6 or 12), omega-3 capsule assignment, or baseline VMS
frequency (Figure 2). In the yoga group, mean hot flash frequency at week 12 decreased to
4.6 (95%CI 3.9, 5.3) VMS/day, a 35% decrease or a mean of 2.9 fewer VMS/day compared
to baseline. The placebo group decreased to 5.4 (95%CI 4.8, 6.1) VMS/day, a 27% decrease
or a mean of 2.6 fewer VMS per day. The mean difference between yoga and usual activity
in the reduction of VMS from baseline to both weeks 6 and 12 was −0.3 VMS/day (6-week
95% CI −1.1,0.5, 12-week 95% CI −1.2, 0.6), overall p=0.119. The mean baseline rating for
VMS bother was 2.9 (95% CI 2.8, 3.0) in the yoga group and 3.0 (95%CI 2.9, 3.1) in the
usual activity group (Table 2). There were no statistically significant differences in change
in VMS bother between baseline and 6 and 12 weeks comparing yoga to usual activity
(overall p=0.417).
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There were no statistically significant interactions between treatment effects and baseline
characteristics on VMS frequency including prior participation in yoga or meditation
(p=0.67), depressive symptoms (p=0.44), BMI (< 25 kg/m2, 25 to ≥30 kg/m2, > 30 kg/m2)
(p=0.37), or race (p=0.48) (Table, Supplemental Digital Content 1, http://links.lww.com/
MENO/A60).
Secondary outcomes
Clinical improvement in VMS at week 12 (≥50% decrease from baseline in VMS frequency)
occurred at a similar rate between the yoga and usual care groups, 36% and 30%,
respectively (p=0.31). The yoga intervention significantly improved insomnia symptoms,
but had no significant impact on anxiety, sleep quality, or depressive symptoms (Table 2).
The mean change in ISI score between baseline and 12 weeks was −4.4 for the yoga
intervention and −3.1 for usual activity (p=0.007).
Among women assigned to yoga, 68% reported at the end of the trial that yoga helped their
menopause symptoms with minimal side effects, 66% reported being satisfied with their hot
flash relief, and 87% said they would like to continue practicing yoga.
Intervention adherence
Participants attended an average of 8.5 ± 3.5 of the 12 scheduled yoga sessions, ranging
from 0 to 13. Women practiced at home an average of 4.1 ± 2.3 times per week. On average,
women did poses 2.6 ± 1.1 times per week and Yoga Nidra 2.3 ± 1.2 times per week.
Results were not altered when analyses were limited to women who were 80% adherent
(attended at least 80% of the yoga classes).
Adverse events
Newly-emergent AEs were reported by 33.7% in the yoga group and 39.3% in the usual
activity group (p=0.41). There were no differences in emergent AEs between groups at any
time point, including muscle aches and strains (6.7% yoga, 10.3% usual activity), low back
pain (4.2% yoga, 3.1% usual activity), or changes in strength or sensation in the arms or legs
(5.5% yoga, 8.9% usual activity). There were no reported serious AEs. Tolerability of
treatment was high; no participants stopped the intervention due to AEs.
DISCUSSION
Based upon the intent-to-treat analysis of this randomized controlled trial we found that a
12-week program of yoga had no effect on VMS frequency or bother when compared to
usual activity. VMS decreased equally in the yoga and usual activity groups over 12 weeks
of intervention. Secondary analyses found no difference in clinical improvement in VMS
frequency but did demonstrate that the yoga intervention improved insomnia symptoms.
Reports from three previous trials of the effects of yoga practice on menopausal symptoms
are generally consistent with our VMS results. Elavsky and colleagues39 studied 4 months of
Iyengar yoga, walking, or usual activity (n=164). There were no significant between group
differences in VMS at 4 months. Positive affect increased in both the walking and yoga
groups compared to the control. In a trial conducted by Afonson and colleagues, 61
postmenopausal women aged 50–65 years with insomnia were randomized to biweekly 1-
hour yoga classes, bi-weekly passive stretching, or usual care.16 They found that compared
to usual care, women assigned to yoga had significant improvement in the Kupperman
Menopause Index, the Insomnia Severity Index, the Menopause-Specific Quality of Life
Questionnaire, and the Inventory of Stress Symptoms for Adults; hot flash frequency was
not measured.16 However, given the extremely high withdrawal rate (23% overall, 63%
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yoga group) these results must be viewed cautiously.40 compared a yoga intervention that
included breathing practices, sun salutation, and cyclic meditation to simple physical
exercises (both 1 hour per day, 5 days a week for 8 weeks) in a randomized controlled trial
of 120 women aged 40–55 years with FSH≥15mIU/ml. At 8 weeks there were no significant
group differences in the change in daytime hot flashes, night sweats, or disturbed sleep.
However yoga resulted in a significant improvement in Greene Climacteric Scale vasomotor
subscale scores.15 In contrast, two small non-randomized yoga studies comparing VMS
symptoms pre and post yoga intervention reported that yoga reduced VMS frequency,
severity, and bother12 as well as severity of menopause-related symptoms, hot-flash daily
interference, and sleep efficiency, disturbances, and quality.14 Interpretation of the results of
these two studies are limited by the lack of a randomized control trial design.
We found that yoga modestly reduced insomnia symptoms, which are common among
women during the menopausal transition41–50 and which can prompt women to seek
therapy.51, 52 While our findings also suggest beneficial effects of yoga on sleep quality and
depressive symptoms, these differences did not reach the level of significance required in
our analyses of the four secondary outcomes. In general, these findings are consistent with
numerous other studies that have found yoga to exert beneficial effects on insomnia,16, 53–56
sleep disturbances,55, 56 and depressive symptoms.13, 57–59
Several limitations are noteworthy. Although this was a community-based sample, the
participants may be a select group motivated to seek treatment and thus our results may not
be generalizable to all women. We examined several potential moderating factors of
treatment response, but other factors likely exist. The overall effect was modest for all
outcomes. The 12-week treatment interval was brief, but data indicate that this interval is
sufficient to determine long-term efficacy of non-hormonal treatments.60, 61 While
participants did keep a home practice log, short of video taping their practice at home it was
impossible to know if their home practice was of equal intensity to the yoga class. We also
cannot rule out the possibility that other yoga approaches might decrease menopause
symptoms. Finally, the “dose” of yoga required to have an effect is not known, including
effects on physiologic parameters of sympathetic/parasympathetic tone. Studies in which
frequency and dose are carefully regulated would be required to answer this question.
Study strengths include the adherence to state-of-the-science randomized trial design, the
design and strict standardization of the yoga intervention, the large sample size, the
inclusion of peri- and postmenopausal women, reasonable adherence to therapy, the
prospective assessment of VMS, and the low dropout rate. The low rates of AEs provide
reassurance that similar yoga programs are safe for midlife women.
CONCLUSIONS
In conclusion, in this randomized controlled trial we found that yoga had no effect on VMS
frequency or bother. However yoga modestly improved insomnia symptoms, another
menopausal symptom important to midlife women. Future trials designed to address the
dose of yoga required to detect meaningful effects on insomnia symptoms, subjective sleep
quality, and depressive symptoms are warranted.
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Figure 1.
Participant recruitment
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Figure 2.
Vasomotor symptom frequency over time by intervention arm, presented as mean +/−
standard error at baseline, week 6, and week 12.
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Table 1
Baseline demographic and clinical characteristics by intervention arm, yoga versus usual activity
Yoga
(N =107)
Usual Activity
(N =142)
N % N %
Age at screening (years), mean (SD) 54.3 (3.9) 54.2 (3.5)
  < 50 7 6.5 10 7.0
  50 – 54 50 46.7 69 48.6
  55 – 59 39 36.4 51 35.9
  60+ 11 10.3 12 8.5
Race
  White 68 63.6 90 63.4
  African American 25 23.4 41 28.9
  Other 14 13.1 11 7.7
Clinical Center
  Indianapolis 36 33.6 48 33.8
  Oakland 33 30.8 44 31.0
  Seattle 38 35.5 50 35.2
Education
  ≤ High school diploma/GED 7 6.5 8 5.6
  School/training after high school 31 29.0 40 28.2
  College graduate 69 64.5 94 66.2
Employment status
  Retired or no employment 14 13.1 18 12.7
  Full-time 60 56.1 91 64.1
  Part-time 17 15.9 17 12.0
  Homemaker 4 3.7 7 4.9
  Other 11 10.3 9 6.3
Married/living with partner 73 68.2 97 68.3
Smoking
  Never 73 68.2 89 62.7
  Past 25 23.4 36 25.4
  Current 8 7.5 16 11.3
Alcohol use (drinks/week)
  0 45 42.1 51 35.9
  1-<7 48 44.9 62 43.7
  7+ 14 13.1 27 19.0
BMI (m/kg2), mean (SD) 27.1 (4.6) 26.9 (4.6)
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Yoga
(N =107)
Usual Activity
(N =142)
N % N %
  <25 39 36.4 49 34.5
  25 – 29 39 36.4 59 41.5
  ≥ 30 29 27.1 34 23.9
Menopause status
  Postmenopausal 80 74.8 116 81.7
  Late transition 24 22.4 23 16.2
  Early transition 3 2.8 3 2.1
Hysterectomy 17 15.9 22 15.5
Bilateral Oophorectomy 8 7.5 13 9.2
Self-reported health
  Excellent 18 16.8 24 16.9
  Very Good 45 42.1 70 49.3
  Good 39 36.4 40 28.2
  Fair 5 4.7 8 5.6
Depression score, mean (SD) 4.0 (3.6) 4.1 (3.6)
  No depression (0–4) 65 60.7 91 64.1
  Mild depression (5–9) 32 29.9 38 26.8
  Moderate+ depression (10+) 9 8.4 11 7.7
Anxiety score, mean (SD) 3.2 (3.8) 3.0 (3.0)
  No anxiety (0–4) 78 72.9 105 73.9
  Mild anxiety (5–9) 21 19.6 30 21.1
  Moderate+ anxiety (10+) 8 7.5 7 4.9
BMI = Body Mass Index
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